Literature DB >> 10908197

Epidemiology of multiple sclerosis in US veterans. VIII. Long-term survival after onset of multiple sclerosis.

M T Wallin1, W F Page, J F Kurtzke.   

Abstract

Survival to 1996 was analysed for nearly 2500 veterans of World War II who were rated as 'service-connected' for multiple sclerosis as of 1956 by the then Veterans Administration. Survival from onset was defined for all white women and black men, and a random sample of white men. Median survival times from onset were 43 years (white females), 30 years (black males) and 34 years (white males). Crude 50-year survival rates were 31.5% (white females), 21.5% (black males) and 16.6% (white males), but only the white females and white males were significantly different. A proportional hazard analysis was used to identify risk factors for mortality from multiple sclerosis onset year. Significant risk factors included male sex (risk ratio: 1.57), older age at onset (risk ratio: 1.05 per year) and high socioeconomic status (risk ratio: 1.05 per socioeconomic status category). There were no statistically significant differences in survival following multiple sclerosis onset by race or latitude of place of entry into military service, both significant risk factors associated with the development of multiple sclerosis. Standardized mortality ratios utilizing national US data (for 1956-96) showed a marked excess for all three race-sex groups of multiple sclerosis cases, with little difference among them, but with a decreasing excess over time. Relative survival rates, used to compare the survival of multiple sclerosis cases with that of other military veterans, did not differ significantly by sex-race group, nor by latitude of place of entry into military service, but did differ significantly by socioeconomic class. The lack of difference in male and female relative survival rates suggests that the significant difference in survival between male and female multiple sclerosis cases is, at least in part, a result of sex per se and not the disease.

Entities:  

Mesh:

Year:  2000        PMID: 10908197     DOI: 10.1093/brain/123.8.1677

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  10 in total

Review 1.  Clinical prognostic factors in multiple sclerosis: a natural history review.

Authors:  Alexandra Degenhardt; Sreeram V Ramagopalan; Antonio Scalfari; George C Ebers
Journal:  Nat Rev Neurol       Date:  2009-12       Impact factor: 42.937

Review 2.  Mortality in patients with multiple sclerosis.

Authors:  Antonio Scalfari; Volker Knappertz; Gary Cutter; Douglas S Goodin; Raymond Ashton; George C Ebers
Journal:  Neurology       Date:  2013-07-09       Impact factor: 9.910

3.  Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.

Authors:  D S Goodin; A T Reder; G C Ebers; G Cutter; M Kremenchutzky; J Oger; D Langdon; M Rametta; K Beckmann; T M DeSimone; V Knappertz
Journal:  Neurology       Date:  2012-04-11       Impact factor: 9.910

4.  Predictors of Mortality in Veterans with Multiple Sclerosis in an Outpatient Clinic Setting.

Authors:  Meheroz H Rabadi; Christopher E Aston
Journal:  Int J MS Care       Date:  2017 Sep-Oct

5.  Analysis of Diagnoses Associated with Multiple Sclerosis-Related In-Hospital Mortality Using the Premier Hospital Database.

Authors:  Frank R Ernst; Jennifer Pocoski; Gary Cutter; David W Kaufman; Dirk Pleimes
Journal:  Int J MS Care       Date:  2016 May-Jun

Review 6.  Measurement and maintenance of reserve in multiple sclerosis.

Authors:  Brian M Sandroff; Carolyn E Schwartz; John DeLuca
Journal:  J Neurol       Date:  2016-04-12       Impact factor: 4.849

7.  Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study.

Authors:  Emmanuelle Leray; Sandra Vukusic; Marc Debouverie; Michel Clanet; Bruno Brochet; Jérôme de Sèze; Hélène Zéphir; Gilles Defer; Christine Lebrun-Frenay; Thibault Moreau; Pierre Clavelou; Jean Pelletier; Eric Berger; Philippe Cabre; Jean-Philippe Camdessanché; Shoshannah Kalson-Ray; Christian Confavreux; Gilles Edan
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

8.  Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.

Authors:  Douglas S Goodin; George C Ebers; Gary Cutter; Stuart D Cook; Timothy O'Donnell; Anthony T Reder; Marcelo Kremenchutzky; Joel Oger; Mark Rametta; Karola Beckmann; Volker Knappertz
Journal:  BMJ Open       Date:  2012-11-30       Impact factor: 2.692

9.  Predictors of Conversion to Multiple Sclerosis in Patients with Clinical Isolated Syndrome Using the 2010 Revised McDonald Criteria.

Authors:  R Alroughani; J Al Hashel; S Lamdhade; S F Ahmed
Journal:  ISRN Neurol       Date:  2012-11-01

10.  Liver kinase B1 rs9282860 polymorphism and risk for multiple sclerosis in White and Black Americans.

Authors:  Anne I Boullerne; Mitchell T Wallin; William J Culpepper; Heidi Maloni; Elizabeth A Boots; Dagmar M Sweeney; Douglas L Feinstein
Journal:  Mult Scler Relat Disord       Date:  2021-08-02       Impact factor: 4.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.